Endocrinopathies and hypertension by Reusch, C
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Endocrinopathies and hypertension
Reusch, C
Reusch, C (2010). Endocrinopathies and hypertension. In: British Small Animal Veterinary Association - BSAVA
Congress, Birmingham, 08 April 2010 - 11 April 2010.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
British Small Animal Veterinary Association - BSAVA Congress, Birmingham, 08 April 2010 - 11 April 2010.
Reusch, C (2010). Endocrinopathies and hypertension. In: British Small Animal Veterinary Association - BSAVA
Congress, Birmingham, 08 April 2010 - 11 April 2010.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
British Small Animal Veterinary Association - BSAVA Congress, Birmingham, 08 April 2010 - 11 April 2010.
Endocrinopathies and hypertension 
Claudia E. Reusch, DVM, Professor, DiplECVIM-CA 
Clinic for Small Animal Internal Medicine, Winterthurerstrasse 260, 8057 Zurich, Switzerland 
 
In dogs and cats, the importance of hypertension was first recognized about 15 – 20 years ago. In 
2007 guidelines similar to those established for humans have been published as Consensus 
Statement of the ACVIM. As blood pressure rises, there is progressive risk of damage to the so called 
end organs or target organs, such as brain, heart, kidney and eye. The most common adverse effects, 
which include hypertensive retinopathy, intraocular hemorrhage and hypertensive encephalopathy, are 
seen when the systolic blood pressure exceeds 180 mmHg, particularly when the increase is acute.  
Hypertension is classified as idiopathic (primary, essential) or secondary. The latter is the most 
prevalent form and is subclassified into renal and endocrine hypertension. The presentation will focus 
on the most common causes of endocrine hypertension in dogs and cats.   
 
Primary aldosteronism  
The first case of feline primary aldosteronism was described in 1983. Since then, the disease has 
been diagnosed with increased frequency, and a little more than 30 cases have now been reported. 
Although no data are available concerning the true prevalence of the disease in the feline population, 
it is assumed that the disease is more common than initially thought. This hypothesis is based on data 
from human medicine, where a more systematic screening revealed a higher than estimated 
prevalence. The majority of human patients diagnosed today have normal potassium levels.  The two 
central mechanisms responsible for the development of hypertension are expansion of plasma and 
extracellular fluid volume and increase in total peripheral vascular resistance. Clinical signs are 
weakness with associated cervical ventroflexion, mydriasis and blindness because of hypertensive 
retinopathy; some cats also have polyuria/polydipsia. Almost all cats described to date have been 
hypokalemic at the time of diagnosis. However, as in human medicine, it may be possible that 
aldosteronism is overlooked in cats with normal potassium levels. The prevalence of hypertension in 
cats with primary aldosteronism is high. Blood pressure was recorded in 30 cases, 26 of which were 
hypertensive. The severity ranged from mild to severe (185 – 270 mmHg), and the most common 
sequels were retinal detachment and ocular bleeding. Initial treatment should be directed towards 
alleviation of hypertension and hypokalemia by using an aldosterone antagonist (spironolactone 2.5 
mg/kg q24h or 6.25 mg/cat q12h PO) and a calcium channel blocker (amlodipine 0.625-1.25 mg/cat 
q24h PO), and substituting potassium as needed. Subsequent adrenalectomy is the treatment of 
choice.  
 
Hyperadrenocorticism  
Hyperadrenocorticism is one of the most common endocrine disorders in dogs. In people hypertension 
is a common complication with a prevalence of between 55% and 80%. The mechanisms by which 
glucocorticoids are involved in the etiology of hypertension are (1) their intrinsic mineralocorticoid 
activity, (2) activation of the renin-angiotensin-aldosterone system (RAAS), (3) enhancement of 
cardiovascular inotropic and pressor activity of vasoactive substances, including catecholamines 
and/or vasopressin and angiotensin II, and (4) suppression of the vasodilatory system, including the 
nitric oxide (NO) synthase, prostacyclin and kinin – kallikrein systems. In dogs with 
hyperadrenocorticism the prevalence of hypertension is similar to that in humans ranging from 59% to 
86%. We recently showed that dogs with experimentally-induced hypercortisolism have significantly 
higher plasma levels of endothelin-1 compared to control dogs. It was also seen that the concentration 
of the ANP precursor (proANP) is lower than that of control dogs. In contrast to current data in human 
medicine, there is no evidence to support reduced NO availability as a cause of increased blood 
pressure.  
A significant proportion of dogs with hyperadrenocorticism (approximately 40%) remain hypertensive 
despite adequate control of the disease. In human medicine, persistent hypertension is treated with 
substances belonging to various classes of drugs, including angiotensin II blockers, ACE inhibitors 
and/or aldosterone antagonists. The use of these drugs in dogs with persistent hypertension despite 
adequate control of hyperadrenocorticism needs to be evaluated.  
 
Pheochromocytoma 
Pheochromocytoma is an uncommon catecholamine-secreting neuroendocrine tumor. In human 
pheochromocytomas, norepinephrine is the predominant catecholamine secreted and in some tumors 
it may be the only catecholamine produced. On rare occasions tumors may secrete only epinephrine. 
The secretory patterns of canine and feline pheochromocytomas have not yet been investigated. 
Catecholamines bind to two types of receptors: ∀- and β-adrenergic receptors, which are further 
subdivided into subtypes. The ∀1 receptor subtype mediates vascular and smooth muscle contraction 
and stimulation of the receptor causes vasoconstriction and increased blood pressure. Activation of ∀2 
receptors inhibits norepinephrine release, suppresses sympathetic outflow and decreases blood 
pressure. Stimulation of β1 receptors results in positive inotropic and chronotropic effects on the heart. 
β2 stimulation causes bronchodilatation and vasodilatation, and β3 receptors regulate energy 
expenditure and lipolysis. 
The clinical presentation is highly variable and ranges from complete absence of signs to dramatic and 
life-threatening signs; the latter is usually the result of a hypertensive crisis. Clinical signs depend on 
the type of catecholamine produced by the tumor and the amount and frequency of catecholamine 
release into the circulation. Ninety to 95% of human patients with pheochromocytoma have 
hypertension. Current information on blood pressure values is limited to less than 50 dogs, 
approximately half of which had hypertension. Similar to the situation in human medicine, the increase 
in blood pressure in dogs may range from mild to severe; the maximum systolic pressure reported was 
325 mmHg. 
Adrenalectomy is the treatment of choice; however, there is a high risk of hypertensive and 
hypotensive crises, cardiac arrhythmias and hemorrhage. α-adrenergic blockade (phenoxybenzamine) 
should be used prior to surgery to reverse vasoconstriction and hypovolemia and control fluctuations 
of blood pressure and heart rate during anesthesia. The starting dose of phenoxybenzamine is 0.25 
mg/kg BID, which is gradually increased until signs of hypotension or adverse drug reaction occur or 
the maximum dose of 2.5 mg/kg BID is attained. A recent study showed that dogs treated with 
phenoxybenzamine had a significantly decreased mortality compared with untreated dogs after 
adrenalectomy.  
 
Hyperthyroidism  
Hyperthyroidism is the most common feline endocrine disease with an estimated prevalence of 2% but 
is rare in dogs. 
In humans with hyperthyroidism systolic arterial pressure is almost always increased. However, the 
disease usually has only minor effects on mean arterial pressure because the increase in systolic 
blood pressure is offset by the decrease in diastolic pressure. Excessive levels of circulating thyroxine 
cause a 40 – 60% decrease in systemic vascular resistance. This decline is accompanied by a 
decrease in diastolic blood pressure, which in turn causes a reflex increase in heart rate, stroke 
volume and cardiac output. The effect of these changes on renal physiology is considerable: a fall in 
systemic vascular resistance induces a decline in renal perfusion pressure, and this stimulates the 
release of renin, leading to increased production of angiotensin. The sum of these changes is 
augmentation of renal sodium reabsorption and expansion of total body sodium content and blood 
volume. An excess of thyroid hormones also leads to increased sensitivity to circulating 
catecholamines resulting in direct induction of inotropy and chronotropy. The prevalence of systemic 
hypertension in the hyperthyroid feline population is estimated to be between 5% and 22%. Severe 
hypertension has been considered uncommon and if documented, concomitant diseases like renal 
failure should be suspected. Chronic kidney disease may be masked at initial presentation because 
the increased glomerular filtration rate induced by hyperthyroidism will maintain urea and creatinine 
levels in the reference range. Azotemia will therefore only become obvious after hyperthyroidism is 
treated, occurring in 17 – 39% of cats.  
Some cats which had been normotensive at the time of diagnosis will develop hypertension during the 
treatment of hyperthyroidism. All of them and the majority of initially hypertensive hyperthyroid cats will 
need additional medication (e.g. amlodipine) to control blood pressure.  
 
Diabetes mellitus 
Diabetes mellitus is one of the most common endocrine diseases in humans as well as dogs and cats. 
In diabetic people, hypertension is a frequently encountered comorbid condition, affecting 10 – 30% of 
patients with type 1 and 30 – 50% of patients with type 2 diabetes mellitus. Possible causes of 
hypertension are loss of the normal vasodilator effect of insulin (e.g. loss of insulin-induced NO 
generation), increase in sodium and water retention, increase in intracellular calcium levels enhancing 
contractility of vascular smooth muscle, proliferation of vascular smooth muscle and stimulation of 
sympathetic outflow. 
Information on blood pressure in diabetic dogs and cats is scarce. It has been shown in dogs with 
newly diagnosed diabetes that although blood pressure is higher than in healthy dogs, most of them 
are not hypertensive. It is possible that hypertension is of greater importance in dogs with long-
standing diabetes. In 50 dogs treated for diabetes for a median of six months, hypertension was 
detected in 23 (46%), a number which compares to the prevalence in human diabetics. There is 
currently no convincing evidence that diabetic cats have hypertension.  
